The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE (2008) Nat Med 14: 748-55 Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC (2007) Blood 110: 1656-63 A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL (2011) Cancer Res 71: 6773-84 Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A (2004) Cancer Res 64: 4912-8 Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Maseda D, Meister S, Neubert K, Herrmann M, Voll RE (2008) Cell Death Differ 15: 600-12 Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG (2010) Clin Cancer Res 16: 3193-204 A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA (2010) Clin Cancer Res 16: 348-57 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC (2011) Clin Cancer Res 17: 3332-40 New drugs on the horizon: matrix metalloproteinase inhibitors. Rothenberg ML, Nelson AR, Hande KR (1999) Stem Cells 17: 237-40 Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J, Murphy BA (2010) Ann Oncol 21: 864-70 Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ (2015) Oncogene 34: 3700-10 Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ (2014) Hypertension 63: 951-7 Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis. Karabela SP, Psallidas I, Sherrill TP, Kairi CA, Zaynagetdinov R, Cheng DS, Vassiliou S, McMahon F, Gleaves LA, Han W, Stathopoulos I, Zakynthinos SG, Yull FE, Roussos C, Kalomenidis I, Blackwell TS, Stathopoulos GT (2012) Carcinogenesis 33: 859-67 Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B (2013) Diabetes Obes Metab 15: 42-54 Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Psallidas I, Karabela SP, Moschos C, Sherrill TP, Kollintza A, Magkouta S, Theodoropoulou P, Roussos C, Blackwell TS, Kalomenidis I, Stathopoulos GT (2010) Mol Cancer 9: 56 A C-terminal fragment of Cyclin E, generated by caspase-mediated cleavage, is degraded in the absence of a recognizable phosphodegron. Plesca D, Mazumder S, Gama V, Matsuyama S, Almasan A (2008) J Biol Chem 283: 30796-803 Thiolytic chemistry of alternative precursors to the major metabolite of the cancer chemopreventive oltipraz. Navamal M, McGrath C, Stewart J, Blans P, Villamena F, Zweier J, Fishbein JC (2002) J Org Chem 67: 9406-13 Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Edwards CM, Lwin ST, Fowler JA, Oyajobi BO, Zhuang J, Bates AL, Mundy GR (2009) Am J Hematol 84: 268-72 Discovery and Characterization of VU0529331, a Synthetic Small-Molecule Activator of Homomeric G Protein-Gated, Inwardly Rectifying, Potassium (GIRK) Channels. Kozek KA, Du Y, Sharma S, Prael FJ, Spitznagel BD, Kharade SV, Denton JS, Hopkins CR, Weaver CD (2019) ACS Chem Neurosci 10: 358-370 A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D (2015) PLoS One 10: e0125482 Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Langouët S, Furge LL, Kerriguy N, Nakamura K, Guillouzo A, Guengerich FP (2000) Chem Res Toxicol 13: 245-52 Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Ciombor KK, Feng Y, Benson AB, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, Amiri KI, Richmond A, Berlin J (2014) Invest New Drugs 32: 1017-27 CI-980 in advanced melanoma and hormone refractory prostate cancer. Ryan CW, Shulman KL, Richards JM, Kugler JW, Sosman JA, Ansari RH, Vokes EE, Vogelzang NJ (2000) Invest New Drugs 18: 187-91 Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen. Reddy N, Greer JP, Goodman S, Kassim A, Morgan DS, Chinratanalab W, Brandt S, Englehardt B, Oluwole O, Jagasia MH, Savani BN (2012) Exp Hematol 40: 359-66 Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group. Gilbert J, Lee JW, Argiris A, Haigentz M, Feldman LE, Jang M, Arun P, Van Waes C, Forastiere AA (2013) Head Neck 35: 942-8 Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH (2013) Cancer Chemother Pharmacol 71: 1567-76 Discovery of VU0431316: a negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bates BS, Rodriguez AL, Felts AS, Morrison RD, Venable DF, Blobaum AL, Byers FW, Lawson KP, Daniels JS, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Emmitte KA (2014) Bioorg Med Chem Lett 24: 3307-14 Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Conde-Ceide S, Alcázar J, Alonso de Diego SA, López S, Martín-Martín ML, Martínez-Viturro CM, Pena MA, Tong HM, Lavreysen H, Mackie C, Bridges TM, Daniels JS, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Lindsley CW, Bartolomé-Nebreda JM (2016) Bioorg Med Chem Lett 26: 429-434
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.